戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  and also has intracellular effects that are antiatherogenic.
2 her mechanism whereby n-3 fatty acids may be antiatherogenic.
3 ect of alpha tocopherol in monocytes that is antiatherogenic.
4 crophage cholesterol efflux and RCT would be antiatherogenic.
5 macrophage-specific overexpression of CEH is antiatherogenic.
6 bjects were categorized as proatherogenic or antiatherogenic according to their capacity to alter the
7 ssion by endothelial cells, suggest that the antiatherogenic action of estrogen may be mediated in pa
8            New mechanistic insights into the antiatherogenic action of n-3 FA have emerged.
9  in peripheral vascular resistance and to an antiatherogenic action.
10 ting anticontractile, anti-inflammatory, and antiatherogenic actions in blood vessels.
11 lin resistance selectively inhibit insulin's antiatherogenic actions via the IRS/PI3K/Akt pathway.
12 activation of IRS/PI3K/Akt results in mostly antiatherogenic actions, as this pathway induces activat
13 ) target genes is linked to antidiabetic and antiatherogenic actions, the mechanisms remain poorly un
14 atherogenic activities from antidiabetic and antiatherogenic activities.
15 c, whereas regulatory T-cell responses exert antiatherogenic activities.
16 , nitric oxide--inducing, antithrombotic and antiatherogenic activity and immune modulation as well a
17 e nonsteroidal LXR agonist GW3965 has potent antiatherogenic activity in two different murine models.
18  naturally occurring mutant with established antiatherogenic activity; however, its relative antiathe
19 ectin is an adipocyte-derived, antidiabetic, antiatherogenic adipocytokine that is present in serum a
20 high-density lipoproteins and seems to be an antiatherogenic agent that prevents initiation and progr
21 rophage IL-10 production can act as a strong antiatherogenic agent, and they highlight a novel antiat
22 aden their indication from lipid-lowering to antiatherogenic agents.
23  characteristics for the evaluation of novel antiatherogenic agents.
24 locally produced NO. and thereby promote the antiatherogenic and anti-inflammatory properties of the
25 altered protein composition might affect the antiatherogenic and antiinflammatory properties of HDL.
26 ng view, this review focuses on the enzyme's antiatherogenic and antiinflammatory properties.
27 ce indicate that the enzyme possesses potent antiatherogenic and antiinflammatory properties.
28           Adiponectin is presumed to possess antiatherogenic and cardioprotective properties.
29 igh-density lipoprotein (HDL)-cholesterol is antiatherogenic and serves a role in mediating cholester
30 rences with diabetes would be expected to be antiatherogenic and the LDL size differences pro-atherog
31         Adiponectin has insulin-sensitizing, antiatherogenic, and anti-inflammatory properties, but l
32  Flavonoid-rich foods have antiinflammatory, antiatherogenic, and antithrombotic properties that may
33  has insulin-sensitizing, anti-inflammatory, antiatherogenic, and cardiomyocyte-protective properties
34 ferative responses, that heme oxygenase-1 is antiatherogenic, and that several studies now show that
35  to apolipoprotein E (apoE), an exchangeable antiatherogenic apolipoprotein.
36          It is possible that estrogen may be antiatherogenic at least in part by increasing plasma ap
37                                       HDL is antiatherogenic because it extracts tissue cholesterol a
38 h-density lipoproteins (HDLs) are considered antiatherogenic because they mediate reverse cholesterol
39                            HDL is considered antiatherogenic, but may have adverse vascular effects i
40 deficiency increases atherosclerosis despite antiatherogenic changes including decreased uptake of re
41 permidine or add-on therapy with widely used antiatherogenic compounds, including statins and metform
42 Falpha) signaling in vascular cells can have antiatherogenic consequences, but the mechanisms are poo
43 rather complex one, either proatherogenic or antiatherogenic, depending on the cell type examined.
44 n of adiponectin with vascular cells and its antiatherogenic effect are connected.
45 es constitutes an important component of the antiatherogenic effect by increasing antioxidant protect
46                                          The antiatherogenic effect in male mice was correlated with
47 efective apoE variants did not replicate the antiatherogenic effect of apoE3.
48 his study demonstrates for the first time an antiatherogenic effect of AT(1) receptor blockade in non
49 he addition of a TP antagonist increases the antiatherogenic effect of COX-1-dependent TxA(2) suppres
50                                          The antiatherogenic effect of ezetimibe monitored by (99m)Tc
51                                  This strong antiatherogenic effect of LA was associated with almost
52                      We hypothesize that the antiatherogenic effect of NO may be due in part to its i
53              These studies indicate that the antiatherogenic effect of NO may be mediated in part by
54 data offer a novel mechanism for a potential antiatherogenic effect of the nitric oxide congener nitr
55 eration (neointimal hyperplasia) may have an antiatherogenic effect.
56 its antiplatelet activity, contribute to its antiatherogenic effect.
57 represent a mechanism of estrogen's apparent antiatherogenic effect.
58  by probucol does not necessarily lead to an antiatherogenic effect.
59 , while suppression of PGE2 accounts for its antiatherogenic effect.
60 mmatory properties that result in a vascular antiatherogenic effect.
61         HDLs mediate a substantial number of antiatherogenic effects along blood vessel walls.
62 r wild-type bone marrow, indicating that its antiatherogenic effects are unrelated to NK-cell depleti
63 itro studies have suggested that PPARs exert antiatherogenic effects by inhibiting the expression of
64 ons demonstrate that NAMPT knockdown exerted antiatherogenic effects by promoting cholesterol efflux
65 se 2 (COX-2) inhibitors may potentially have antiatherogenic effects by virtue of inhibiting inflamma
66        Partial ACAT inhibition by F-1394 had antiatherogenic effects in apoE-deficient mice that were
67 gs suggest that PPARgamma agonists may exert antiatherogenic effects in diabetic patients and provide
68 ells, including macrophages, may exert local antiatherogenic effects independent of plasma lipid chan
69      Furthermore, these drugs promote direct antiatherogenic effects of HDL (antioxidation, anti-infl
70 herogenesis by counteracting the established antiatherogenic effects of HDL and the ATP-binding casse
71   It is becoming increasingly clear that the antiatherogenic effects of HDL are not only dependent on
72                     This article reviews the antiatherogenic effects of HDL, recent insights into the
73 ials, recent work has confirmed the putative antiatherogenic effects of hormone-replacement therapy o
74                          Consistent with the antiatherogenic effects of miR-223 in vitro, mice receiv
75 ght to document the common mechanisms of the antiatherogenic effects of the cholesterol-lowering hydr
76 thway; however, the structural basis for its antiatherogenic effects remains poorly understood.
77 ceride and cholesterol levels, but potential antiatherogenic effects should be assessed in future stu
78            Statins have antiinflammatory and antiatherogenic effects that have been attributed to inh
79  exerts anti-inflammatory, antidiabetic, and antiatherogenic effects through its receptors (AdipoRs),
80 that PPARalpha expression by macrophages has antiatherogenic effects via modulation of cell cholester
81 ensity lipoprotein receptor protein 1 exerts antiatherogenic effects via pathways independent of apoE
82             Atorvastatin exerted significant antiatherogenic effects, and (99m)Tc-cAbVCAM1-5 lesion u
83 nsulin sensitivity, has antiinflammatory and antiatherogenic effects, and is associated with a lower
84 otes reverse cholesterol transport and other antiatherogenic effects, interventions aimed at raising
85 iding a novel mechanism whereby IGF-1 exerts antiatherogenic effects.
86 d that inhibition of SM synthesis would have antiatherogenic effects.
87 expression are likely to contribute to their antiatherogenic effects.
88 n adipokine facilitating insulin action, has antiatherogenic effects.
89 hormone that has shown anti-inflammatory and antiatherogenic effects.
90 iatherogenic activity; however, its relative antiatherogenic efficacy compared with that of wild-type
91 -containing lipoproteins, whereas LCAT is an antiatherogenic enzyme that facilitates reverse choleste
92  vascular damage and inactivated 2 important antiatherogenic enzymes, prostacyclin synthase and eNOS.
93 nd c9,t11-CLA may be hypocholesterolemic and antiatherogenic, epidemiologic data comparing rTFAs and
94 ensity lipoproteins (HDL) and an established antiatherogenic factor.
95 ty lipoproteins, the molecular basis for its antiatherogenic function is elusive, in part because of
96                     Here, we discuss the HDL antiatherogenic functions in relation to oxidative modif
97 nd isolevuglandins, dramatically impairs the antiatherogenic functions of HDL.
98 he immune system also has important pro- and antiatherogenic functions.
99 lpha S198 phosphorylation, including that of antiatherogenic genes such as CCR7.
100 e long run allow us to selectively switch on antiatherogenic genes, and switch off proatherogenic gen
101 ontaining lipoproteins and a decrease in the antiatherogenic HDL cholesterol.
102                        PON1 is a potentially antiatherogenic HDL-associated enzyme that protects LDL
103 (CETP) transports cholesteryl ester from the antiatherogenic high-density lipoproteins (HDL) to the p
104 t disruption of the balance between pro- and antiatherogenic immune cell subsets may trigger clinical
105 , we discuss the novel concept that pro- and antiatherogenic immune responses toward unknown arterial
106 complete deficiency of ACAT1 activity is not antiatherogenic, in part because of toxicity resulting f
107 % of the significant association between the antiatherogenic interleukin (IL) 13 and mortality.
108 reverse cholesterol transport it promotes an antiatherogenic lipid environment in the vascular wall.
109 e, and ischemic stroke, with a corresponding antiatherogenic lipid profile, and with increased longev
110 lasma triglycerides (P < 0.001), promoted an antiatherogenic lipoprotein profile, and induced a more
111  at least some critical concentration of the antiatherogenic lipoprotein, is required for D-4F to dec
112  by affecting the balance of atherogenic and antiatherogenic lipoproteins in plasma, and by modulatin
113 I and on-treatment levels of atherogenic and antiatherogenic lipoproteins, and C-reactive protein, in
114 h reflects the balance of proatherogenic and antiatherogenic lipoproteins, is a risk marker or a risk
115  reverse cholesterol transport, the putative antiatherogenic mechanism by which human plasma high-den
116           One of the most important of these antiatherogenic mechanisms is RCT, a series of reactions
117 d capacity for endothelial production of the antiatherogenic molecule nitric oxide (NO), which is gen
118 NOS), leading to increased production of the antiatherogenic molecule NO.
119 a natural ER stress reliever that induced an antiatherogenic monocyte/macrophage phenotype.
120 tructure, which may relate to differences in antiatherogenic potential.
121 ncrease its plasma half-life and in turn its antiatherogenic potential.
122 o HDL, leading to an increase in potentially antiatherogenic prebeta-HDL particles.
123 mation of mature (spheroidal) HDL during the antiatherogenic process of reverse cholesterol transport
124  been linked with various proatherogenic and antiatherogenic processes.
125             To date, both proatherogenic and antiatherogenic properties have been assigned to B cells
126 tinic acid has been used for decades for its antiatherogenic properties in humans.
127  increases its plasma half-life and enhances antiatherogenic properties in vivo.
128 the results of this study, we infer that the antiatherogenic properties of 4F may result from its pre
129                                          The antiatherogenic properties of apoA-IV suggest that this
130 apo A-IV levels influence the metabolism and antiatherogenic properties of HDL.
131  macrophage sterol efflux are central to the antiatherogenic properties of HDL.
132 ) particles and is believed to contribute to antiatherogenic properties of HDLs.
133 the current understanding of the potentially antiatherogenic properties of high-density lipoprotein r
134 ay be an additional mechanism underlying the antiatherogenic properties of nut intake.
135 he reverse cholesterol transport pathway and antiatherogenic properties of this protein.
136 th HDL determines their antiinflammatory and antiatherogenic properties regardless of their ability t
137 ex role in lipoprotein metabolism, with some antiatherogenic properties such as the maintenance of a
138 evels of marine-derived n-3 fatty acids have antiatherogenic properties that are independent of tradi
139  in the liver and in macrophages, and it has antiatherogenic properties that are mediated, at least i
140 n sensitivity, exhibits antiinflammatory and antiatherogenic properties, and has been linked to sever
141 ytokine that possesses anti-inflammatory and antiatherogenic properties, frequently observed among ob
142 le with antidiabetes, anti-inflammatory, and antiatherogenic properties, provides a novel and unique
143  have been shown to be responsible for their antiatherogenic properties, we undertook high resolution
144  have been shown to be responsible for their antiatherogenic properties, we undertook high resolution
145 s insulin-sensitizing, antiinflammatory, and antiatherogenic properties.
146 ntial anti-inflammatory, antithrombotic, and antiatherogenic properties.
147 yslipidemic derivatives with antioxidant and antiatherogenic properties.
148 sively studied for its anti-inflammatory and antiatherogenic properties.
149  HDL contributes to its antiinflammatory and antiatherogenic properties.
150 s, 3F-2 and 3F(14), differ in their in vitro antiatherogenic properties.
151 evidence indicate that the enzyme has strong antiatherogenic properties: (1) it inhibits the effects
152                                          The antiatherogenic property of estrogens is mediated via at
153 otic effects that may represent an important antiatherogenic property of the lipoprotein.
154  lipoprotein (HDL), has been associated with antiatherogenic protection by mechanisms that include re
155 teome, already revealing unsuspected pro- or antiatherogenic proteins/peptides associated with HDL.
156                                          The antiatherogenic quality of HDL is defined by the functio
157 pression recapitulated the proatherogenic or antiatherogenic regulation of VCAM-1.
158 y used medication can increase expression of antiatherogenic reverse cholesterol transport proteins a
159 l epidemiology human studies both support an antiatherogenic role for 12/15-lipoxygenase downstream a
160 risk of CHD and apoAIV levels, supporting an antiatherogenic role for apoAIV.
161             These findings establish a novel antiatherogenic role for IL-27 receptor signaling, which
162  phospholipase A2, plays a proatherogenic or antiatherogenic role in atherosclerosis, many recent rev
163              Thus, macrophage SR-BI plays an antiatherogenic role in vivo, providing a new therapeuti
164 by a modified HDL theory that emphasizes the antiatherogenic role of cholesterol flux pathways, initi
165          Our results present a comprehensive antiatherogenic role of IL10 in macrophages, including e
166                                 However, its antiatherogenic role remains controversial.
167 ipids stimulate the production of the potent antiatherogenic signaling molecule NO by the vascular en
168                      Here, we propose a dual-antiatherogenic strategy for administration of the LXR a
169  cholesterol transport (RCT), is a promising antiatherogenic strategy.
170 ecrosis factor]) or as anti-inflammatory and antiatherogenic (such as IL-10 and IL-1rA).
171           Omega3-PUFA mimicked the effect of antiatherogenic TGRL by downregulating VCAM-1 expression
172 h tumor necrosis factor-alpha alone, whereas antiatherogenic TGRL decreased VCAM-1 expression by appr
173 ty that their antiinflammatory effect may be antiatherogenic, this study investigated the effect of g
174 s linked to reduced diabetes risk and may be antiatherogenic, yet clinical data show no consistent re

 
Page Top